Landos (LABP) Secures AbbVie Deal: Propelling Novel Oral Therapy Development
Landos (LABP) Secures AbbVie Deal: Propelling Novel Oral Therapy Development
The current surge of Landos Biopharma, Inc. (NASDAQ: LABP) shares on the US charts, marking a notable surge of 168.27% to $21.46 per share as of the last check, is attributed to a takeover bid.
Landos Biopharma, Inc.（納斯達克股票代碼：LABP）目前在美國排行榜上的股價飆升，截至上次支票時每股大幅上漲168.27％，至21.46美元，這歸因於收購要約。
Today, Landos (LABP) disclosed a definitive agreement with AbbVie Inc., outlining AbbVie's intent to acquire Landos. At the forefront of Landos' offerings is NX-13, a pioneering oral NLRX1 agonist boasting a bimodal mechanism of action (MOA), renowned for its anti-inflammatory properties and its facilitation of epithelial repair.
今天，蘭多斯（LABP）披露了與艾伯維公司達成的最終協議，概述了艾伯維收購蘭多斯的意圖。Landos 產品的前沿是 NX-13，這是一種開創性的口服 NLRX1 激動劑，具有雙模態作用機制 (MOA)，以其抗炎特性和促進上皮修復而聞名。
The acquisition underscores AbbVie's strategic pursuit to propel the clinical progression of NX-13, distinguished for its innovative oral formulation and its potential to ameliorate the conditions of individuals grappling with ulcerative colitis and Crohn's disease.
此次收購凸顯了艾伯維推動 NX-13 臨床進展的戰略追求。以其創新的口服配方及其改善潰瘍性結腸炎和克羅恩病患者病情的潛力而著稱。
This announcement epitomizes Landos' steadfast dedication to its mission of developing oral therapeutics tailored to fill existing treatment voids. NX-13, along with its bimodal MOA, presents a promising avenue for addressing the complexities of ulcerative colitis and Crohn's disease.
該公告體現了Landos堅定不移地致力於開發量身定製的口服療法以填補現有治療空白的使命。NX-13 及其雙模式 MOA 爲解決潰瘍性結腸炎和克羅恩氏病的複雜性提供了一個有希望的途徑。
Given AbbVie's proficiency in therapeutic domains and its global development acumen, the company is poised to advance NX-13 effectively. NLRX1 serves as a pivotal regulator of immunometabolism and inflammation, with its activation influencing various facets of inflammatory bowel disease (IBD) pathogenesis.
鑑於艾伯維在治療領域的熟練程度及其全球開發敏銳度，該公司準備有效推進 NX-13。NLRX1 是免疫代謝和炎症的關鍵調節劑，其激活會影響炎症性腸病 (IBD) 發病機制的各個方面。
Currently, the randomized controlled Phase 2 NEXUS clinical trial evaluating NX-13 in ulcerative colitis is actively enrolling patients across the United States and Europe (NCT05785715). Per the terms delineated in the agreement, AbbVie is set to acquire Landos at a per-share price of $20.42 in cash upon closure, totaling approximately $137.5 million.
目前，評估 NX-13 治療潰瘍性結腸炎的隨機對照 2 期 NEXUS 臨床試驗正在積極招收美國和歐洲各地的患者（NCT05785715）。根據協議中規定的條款，艾伯維將在收盤時以每股20.42美元的現金價格收購蘭多斯，總額約爲1.375億美元。
Additionally, the deal incorporates a non-tradable contingent value right per share, valued at up to $11.14, amounting to an additional approximately $75 million contingent upon the attainment of a clinical development milestone. The anticipated finalization of the transaction is slated for the second quarter of 2024, pending customary closing prerequisites, including approval from Landos' shareholders.
此外，該交易還包括每股不可交易的或有價值權，價值最高爲11.14美元，總額約爲7,500萬美元，視臨床開發里程碑的實現而定。該交易預計將於2024年第二季度完成，尚待包括Landos股東批准在內的慣例成交先決條件。